ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Integrated Metabolomic and Transcriptomic Profiling Reveals a Distinct Pathological Aging State in Diminished Ovarian Reserve of Advanced Reproductive-Age Women.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Women of advanced age exhibit significant heterogeneity in ovarian reserve, categorized as normal (NOR) or diminished (DOR). This study aims to distinguish physiological age-related decline from pathological accelerated aging in DOR, and to explore underlying molecular mechanisms for optimizing assisted reproductive strategies. In vitro fertilization-embryo transfer (IVF-ET) outcomes were retrospectively compared in advanced-age women (≥ 40 years) with NOR or DOR treated at our center (January 2022 - December 2024). Simultaneously, follicular fluid (FF) was collected from both groups (n = 20). After centrifugation, metabolomic analysis was performed on metabolites, and transcriptomic sequencing on isolated granulosa cells (GCs). Despite comparable fertilization and cleavage-stage embryo quality, the DOR group showed significantly lower rates of oocyte maturation, blastocyst formation, clinical pregnancy, and live birth (P < 0.05). Metabolomic analysis revealed 28 differential metabolites (DMs) in FF, primarily enriched in galactose metabolism. Transcriptomics of GCs identified 246 differentially expressed mRNAs (DEmRNAs), prominently enriched in immune-related pathways. Protein-protein interaction analysis highlighted five hub genes (CX3CR1, CD69, FCER1A, EOMES, SPRR2A). Integrated analysis of the top 50 DEmRNAs with the top 400 DEmRNA-DM correlation pairs identified five key genes-IGLC3, RNVU1-29, FAM110C, NPY2R, and KCNN4-bridging GC transcriptome and FF metabolome, with key pairs including RNVU1-29 with lysylhydroxyproline and a sterane derivative, and FAM110C with 16-hydroxyhexadecanoic acid. In conclusion, DOR in advanced age may represent a distinct pathological aging state characterized by a dysregulated follicular microenvironment potentially shaped by immune activation and metabolic reprogramming. The identified key gene-metabolite pairs offer candidate molecular links to compromised oocyte developmental competence.
Indexed as
Identifiers
42426427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.